Delving into the Latest Updates on Choriogonadotropin alfa with Synapse

Overview

Basic Info

Drug Type

Peptide Hormone

Synonyms

Choriogonadotropin Alfa (Genetical Recombination), Choriogonadotropin alfa (genetical recombination) (JAN), Choriogonadotropin alfa (USAN/INN)

+ [11]

Target

FSHR x LHCGR

Action

agonists

Mechanism

FSHR agonists(Follicle-stimulating hormone receptor agonists), LHCGR agonists(Luteinizing hormone/Choriogonadotropin receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication

AnovulationInfertility, FemaleInfertility+ [1]

Inactive Indication

Functional disorderHypothalamic DiseasesPolyendocrine Metabolic Ovarian Syndrome

Originator Organization

Merck Serono SA

Active Organization

Fresenius SE & Co. KGaAMerck Healthcare Pty Ltd.Merck Europe BV

+ [4]

Inactive Organization

Merck KGaA

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (05 Mar 1973),

Hypogonadism

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 3246

Source: *****

Sequence Code 51997

Source: *****

The COGNI-REHAB Trial is a single-site, phase O/I, randomized, double-blind, placebo-controlled study of human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) in men with post-acute, moderate to severe traumatic brain injury (msTBI). Its objective is to assess the safety and efficacy of a 24-week regimen of Ovidrel (125 micrograms twice weekly) compared to placebo on treatment-emergent adverse events (TEAEs), cognitive and functional recovery, and circulating sex hormones.

Start Date01 Oct 2026

Sponsor / Collaborator

VA Office of Research and Development

CTIS2026-526292-37-01

/ RecruitingPhase 4IIT

Phase IV randomized, single-blind clinical trial with three parallel arms to compare ovulation triggering strategies in IVF cycles with fresh embryo transfer.

Start Date14 Jul 2026

Sponsor / Collaborator-

NCT07425990

/ Not yet recruitingNot ApplicableIIT

FET-LET-2x2: A Randomized Open-Label 2×2 Factorial Trial Comparing Clinical Pregnancy Rates After Frozen Embryo Transfer in True and Modified Natural Cycles With and Without Aromatase Inhibitors

The goal of this clinical trial is to learn whether different natural approaches to preparing the uterus for frozen embryo transfer (FET) can improve pregnancy success in women undergoing in vitro fertilization (IVF) treatment.
The main questions it aims to answer are:
1. Is a completely natural menstrual cycle more successful than a natural cycle in which ovulation is triggered with medication when preparing for frozen embryo transfer?
2. Does taking a medication called letrozole at the beginning of the cycle improve pregnancy success compared to not taking it?
Researchers will compare four different approaches to see which one results in the highest chance of achieving a clinical pregnancy, confirmed by ultrasound.
Participants will:
* Be randomly assigned to one of four groups
* Undergo monitoring with ultrasound and blood hormone tests during their menstrual cycle
* In some groups, take letrozole tablets for a few days early in the cycle
* In some groups, receive a hormone injection to help control the timing of ovulation
* Undergo frozen embryo transfer at the appropriate time
* Receive standard hormonal support after embryo transfer
* Researchers will compare four different approaches to see which one results in the highest chance of achieving a clinical pregnancy, confirmed by ultrasound.

Start Date01 Feb 2026

Sponsor / Collaborator

University of Novi Sad

100 Clinical Results associated with Choriogonadotropin alfa

Login to view more data

100 Translational Medicine associated with Choriogonadotropin alfa

Login to view more data

100 Patents (Medical) associated with Choriogonadotropin alfa

Login to view more data

236

Literatures (Medical) associated with Choriogonadotropin alfa

08 Sep 2026·ONCOGENE

mTORC1 activation induces B7-H3-dependent metabolic reprogramming in renal cell carcinoma (RCC)

Article

Author: Daou, Melissa ; Liu, Heng-Jia ; Henske, Elizabeth P ; Wang, Yifan ; Li, Keying ; Du, Heng ; Asara, John M ; Kwiatkowski, David J ; Alchoueiry, Michel ; Khabibullin, Damir

Abstract:

Renal cell carcinoma (RCC) affects over 435,000 people worldwide each year and remains a significant cause of cancer mortality. Aberrant activation of pathways such as mTORC1 is frequently observed in RCC, yet the mechanisms by which mTORC1 contributes to tumor development remain poorly understood. The lack of suitable animal models has limited progress in uncovering these mechanisms and advancing targeted treatments. Here, we performed single-cell transcriptomic, proteomic, and metabolomic profiling of kidneys from mice with embryonic Tsc2 deletion at E17.5, which revealed a distinct tumor cell population characterized by intercalated cell signatures, co-expression of Foxi1 and Rhcg , and hyperactivated mTORC1. These lesions closely resemble human chromophobe renal cell carcinoma (ChRCC), a subtype of RCC. The tumors show marked upregulation of the immune checkpoint molecule B7-H3. Mechanistically, the transcription factor NRF1 is elevated in Tsc2 -deficient lesions and drives B7-H3 expression in tumor cells. In human specimens, B7-H3 is broadly expressed in both classical and sarcomatoid ChRCC and correlates with hallmark markers FOXI1, MUC2, and HEPACAM2. Strikingly, B7-H3 deletion in mice suppresses Tsc2 loss-driven cystic and tumor formation, restores amino acid metabolism, and attenuates aminoacyl-tRNA biosynthesis and proteasome activity. Collectively, these findings identify B7-H3 as a functional driver of Tsc2 -mediated ChRCC and a promising therapeutic target in TSC-associated renal tumors.

01 May 2026·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Genome-wide analysis of the Rh gene family in Gymnocypris eckloni and its role in ammonia transport under carbonate alkalinity stress

Article

Author: Tian, Fei ; Liu, Dan ; Qi, Delin ; Zhang, Cunfang ; Xia, Mingzhe ; Yao, Zhanwen ; Guo, Shouquan ; Li, Ying ; Nie, Miaomiao

This study investigated the role of the Rhesus (Rh) gene family in the adaptation to high alkalinity in Gymnocypris eckloni. We employed bioinformatic analysis of the Rh gene family based on G. eckloni genome data, along with alkalinity stress experiments and gene expression analysis. The results revealed that the Rh gene family in G. eckloni comprises seven members, encoding proteins ranging from 425 to 489 amino acids. Analyses of the motifs, domains, and gene structure all indicated high conservation among family members, albeit with considerable variation in gene structure. Chromosomal localization showed that the Rh genes were distributed across six chromosomes. Predictions of subcellular localization and transmembrane helices confirmed that Rh glycoproteins are transmembrane proteins containing 9-12 transmembrane helices. Under carbonate alkalinity stress, blood ammonia levels in G. eckloni gradually increased and then declined after 48 h of exposure. Gene expression studies demonstrated significant upregulation of Rhag, Rhbg, and Rhcg2a in gill tissue and Rhbg, Rhcg2a, and Rhcg2b in skin tissue after stress exposure. In the kidney, Rhag and Rhcg1 were significantly upregulated, with Rhd exhibiting the highest expression levels. In contrast, liver gene expression was generally low, with only Rhcg2a and Rhcg2b showing significant upregulation after prolonged, high-concentration stress exposure. Western blot analysis of selected Rh proteins (Rhag, Rhbg, Rhcg) in the gill, skin, and kidney revealed that their expression was upregulated following alkalinity stress, largely consistent with the trends observed at the transcript level. This further elucidated the tissue-specific roles of Rh gene family members in ammonia transport: in gill tissue, Rhag, Rhbg, Rhcg1, and Rhcg2a coordinately participate in the ammonia excretion process; in skin tissue, ammonia excretion is primarily mediated by Rhbg, Rhcg2a, and Rhcg2b; in kidney tissue, Rhcg1 plays a key role, and this process may be independent of Rhbg. In contrast, the liver plays a relatively limited role in ammonia excretion. Based on gene expression data, Rhd appears unrelated to ammonia excretion. Although the expression trends of Rh50 (transcript level) paralleled those of Rhag across tissues, its specific function requires further investigation.. This study reveals the expression patterns and suggests potential roles of Rh gene family members in ammonia transport in G. eckloni, providing a preliminary scientific basis for further functional studies and the conservation of this species.

01 Apr 2026·HISTOLOGY AND HISTOPATHOLOGY

RHCG inhibition promotes the sensitivity of PIK3CA-mutant non-small lung cancer to PI3K inhibitor.

Article

Author: Wang, Muqun ; Liu, Haitao ; Pang, Yingying

PIK3CA, the gene encoding the catalytic subunit of the PI3K complex, is significantly amplified and mutated in several cancer forms, including non-small cell lung cancer (NSCLC). Although follicular lymphoma and chronic lymphocytic leukemia have been treated clinically with PI3K inhibitors, there are currently no FDA-approved medications targeting PI3K mutations in lung cancer. In this study, by TCGA database analysis, we found that RHCG was highly expressed in PIK3CA-mutated NSCLC and was associated with poor prognosis. Knockdown of RHCG in PIK3CA-mutated NSCLC inhibited cell proliferation and promoted apoptosis, thereby sensitizing cells to PI3K inhibitors. Mechanistically, the knockdown of RHCG acts synergistically with PI3K inhibitors to produce more effective inhibition of AKT and S6RP phosphorylation downstream of PI3K. This finding suggests a potential NSCLC target with PIK3CA mutations.

4

News (Medical) associated with Choriogonadotropin alfa

25 Feb 2026

·www.biospace.com

Trump Calls on Congress To Codify Most Favored Nation Drug Pricing in SOTU

White House , screengrab In his State of the Union address on Tuesday evening, President Donald Trump urged Republican leaders to pass legislation cementing his new drug pricing initiatives as he touted his efforts to lower healthcare costs for Americans. President Donald Trump called on Congress to codify his Most Favored Nation drug pricing initiative into law, as he delivered the State of the Union address at the Capitol in Washington, D.C. on Tuesday evening. He also touted his efforts to lower drug prices and the success of deals with pharma companies that were signed over the fall. “Under my just enacted Most Favored Nation agreements, Americans who have for decades paid by far the highest prices of any nation anywhere in the world for prescription drugs will now pay the lowest price anywhere in the world for drugs,” Trump said, according to a transcript of the event. “I took prescription drugs, a very big part of healthcare, from the highest price in the entire world to the lowest. That’s a big achievement.” The White House launched the TrumpRx platform in February , offering select drugs from major pharma companies on a direct-to-consumer basis. Analysts have been skeptical of the program’s ability to lower out-of-pocket costs for patients, as many of the drugs offered were heading for a patent cliff and would be lowered anyway. Other experts also questioned the impact of the program, which would likely only serve uninsured patients or those with high-deductible plans. Most patients would have access to steeper discounts via their regular insurance plans. Pfizer was the first company to sign an MFN deal last year, soon to be followed by the likes of AstraZeneca, Amgen, Bristol Myers Squibb and more. The CEOs of Eli Lilly and Novo Nordisk attended a joint announcement at the White House in November to offer their GLP-1 products, including initial doses of upcoming oral weight loss medicines, for $150. Many of the companies reached the agreements in exchange for exemption from tariffs. Drug pricing How Effective Will TrumpRx and Other Direct-to-Consumer Drug Pricing Initiatives Be? With pricing pressures climbing, Pfizer, Eli Lilly and other major drugmakers are looking to sell their products directly to patients. Analysts are skeptical that these efforts, including those announced to much fanfare from the White House, will result in meaningful reductions in drug spending. November 12, 2025 · 11 min read · Tristan Manalac Read More Trump said the TrumpRx platform has lowered drug prices “300, 400, 500, 600 percent and more.” The president specifically pointed to medicines for in vitro fertilization, which are not typically covered by insurance plans. In October, Merck KGaA’s U.S. subsidiary EMD Serono announced an agreement with the U.S. government to broaden access to its fertility medications, including Gonal-F, Ovidrel and Cetrotide. In his address, Trump called out one patient in attendance who was able to access IVF medications for less, Catherine Rayner. Rayner was the first person to utilize the TrumpRx platform, according to the president. “One drug has been costing Catherine $4,000 to purchase. But a few weeks ago, she logged on to the website and got that same drug that cost costs $4,000, got it for under $500, a reduction of much more actually than $3,500,” Trump said. “Catherine, we are all praying for you and you’re going to be a great mom.” With Rayner as an example, Trump urged his Republican leaders in Congress to codify Most Favored Nation drug pricing. “I’m not sure it matters because it’s going to be very hard for somebody that comes along after me to say, let’s raise drug prices by 700 or 800 percent. But John and Mike, if you don’t mind, codify it anyway,” he said, referring to Senate Majority Leader John Thune and House Speaker Mike Johnson. Trump already urged Congress to address MFN in a January announcement of “The Great Healthcare Plan,” which seeks to take the drug pricing fight to insurers. Drug pricing Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026 Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller biotechs continue to hang in limbo. January 6, 2026 · 5 min read · Annalee Armstrong Read More

17 Oct 2025

·www.fiercepharma.com

Merck KGaA's EMD Serono strikes MFN deal in Trump's fertility treatment pricing push

Merck KGaA’s U.S. arm EMD Serono is the latest to join President Donald Trump's most-favored nation pricing push, following AstraZeneca and Pfizer. Merck KGaA’s U.S. arm EMD Serono is joining President Donald Trump’s most-favored nation drug pricing push with an agreement to sell its fertility therapies at a sharp discount through the government’s TrumpRx direct-to-consumer purchasing platform.The company will offer its full in vitro fertilization (IVF) drug portfolio, including Gonal-f, Cetrotide and Ovidrel, to eligible patients, with an 84% discount for the use of all three therapies in a typical IVF regimen when TrumpRx goes live in 2026. Citing the Centers for Medicare & Medicaid Services, the White House said the price cuts could save patients up to $2,200 per IVF cycle. Fertility medications make up almost 20% of the total cost of treatment, which can total between $15,000 and $30,000 for one round, according to GoodRx. The new public-private partnership with EMD Serono complies with Trump’s February executive order on expanding access to IVF, the company said in a Thursday press release. The White House said EMD Serono will offer other drugs at deep discounts when sold directly to patients and guarantee MFN prices on new medicines, while the company separately said it reached a Commerce Department agreement to exclude its products from Section 232 tariffs in return for U.S. manufacturing and research investments.EMD Serono already has a strong U.S. presence and looks “forward to growing our footprint here even further with future fertility manufacturing,” CEO of Merck KGaA, Darmstadt, Germany’s Belén Garijo said in the company's release.“We are committed to working with the U.S. administration to add value over the long term, ensuring that our patients and customers continue to have access to and benefit from the innovations within our portfolio,” Garijo added.According to the White House, the agreement marks the “first time in history” that EMD Serono is investing in U.S. manufacturing. The company has long operated in the U.S. and moved its headquarters to Boston in 2023.EMD Serono’s Gonal-f was first approved in the late 90s as one of the first recombinant human products used to treat infertility. Since then, the Merck KgaA unit has built out its fertility franchise to include other complementary products and devices, with the next addition now coming to the U.S. sooner, with a potential FDA Commissioner’s National Priority Voucher (CNPV).CNPV for IVF The company’s Pergoveris, a combination of recombinant human follicle-stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) that’s designed to “mimic reproductive physiology,” will soon be filed for FDA review under its CNPV program. The program applies to products that align with U.S. national health priorities and reduces the FDA’s review timeline from about 10 to 12 months to one to two months. FDA Commissioner Marty Makary, M.D., launched the CNPV program in June and announced the first nine recipients on Oct. 16. Other than EMD Serono’s Pergoveris for infertility, investigational products from Regeneron, Sanofi and others made the cut to treat diseases ranging from diabetes, deafness and blindness, to name a few.Pergoveris is already widely available outside the U.S. If it wins U.S. approval, the White House said patients could benefit further from lower prices thanks to increased competition in the fertility drug market.Along with the administration’s deal with EMD Serono, it announced new guidance for employers to offer standalone benefit packages for IVF and infertility. One in 8 U.S. couples struggles with fertility, according to EMD Serono, which describes itself as “the leader in fertility therapeutics.”EMD Serono joins AstraZeneca and Pfizer in complying with Trump’s MFN pricing demands, which look to tie U.S. prices to lower costs overseas. Much of the deal implores companies to sell their drugs directly to patients, which many have already embraced. Others, like Bristol Myers Squibb, will roll out their drugs in the U.K. at higher U.S.-linked prices.

Drug Approval

17 Oct 2025

·www.pharmaceutical-technology.com

EMD Serono partners US government to widen IVF access

Patients will have access to an expanded network from early 2026 and all EMD Serono’s fertility medications. Credit: MidoSemsem/Shutterstock.com. Merck’s healthcare division in Canada and the US, EMD Serono, has signed an agreement with the Trump administration to expand access to the company’s in vitro fertilisation (IVF) therapies for more than 10 million American women struggling to conceive. EMD Serono agreed to provide direct-to-consumer (DTC) sales of its entire range of IVF therapies, including Ovidrel (choriogonadotropin alfa injection), Cetrotide (cetrorelix acetate for injection) and Gonal-f (follitropin alfa injection), to qualified patients with prescriptions at lower prices. When all three therapies are included in a standard IVF protocol, patients will benefit from an 84% reduction on list prices. EMD Serono is set to take part in the TrumpRx.gov direct purchasing platform, scheduled to launch in January 2026. Patients will have access to an expanded network available from early next year, as well as all of EMD Serono’s fertility medications through the company’s current pharmacy network. This public-private partnership is in accordance with the White House Executive Order aimed at enhancing affordable access to IVF. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence EMD Serono has also reached an agreement with the US Secretary of Commerce to exempt its pharmaceutical products and ingredients from Section 232 tariffs, contingent upon the company’s investment in future biopharmaceutical manufacturing and research in the US. Merck executive board chair and CEO Belén Garijo stated: “We have a strong presence in the US across all three of our business sectors, with a significant number of our employees based in this key market, and look forward to growing our footprint here even further with future fertility manufacturing. “We are committed to working with the US administration to add value over the long term, ensuring that our patients and customers continue to have access to and benefit from the innovations within our portfolio.” In September 2025, Merck and Siemens signed a memorandum of understanding (MoU) to enhance their strategic partnership, aimed at accelerating digital transformation in the life sciences sector. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

100 Deals associated with Choriogonadotropin alfa

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03478	Choriogonadotropin alfa	G03GA08	DB00097

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anovulation	Australia	Merck Healthcare Pty Ltd.	17 Sep 2003
Infertility, Female	European Union	Merck Europe BV	02 Feb 2001
Infertility, Female	Iceland	Merck Europe BV	02 Feb 2001
Infertility, Female	Liechtenstein	Merck Europe BV	02 Feb 2001
Infertility, Female	Norway	Merck Europe BV	02 Feb 2001
Infertility, Female	United Kingdom	Merck Serono Ltd.	02 Feb 2001
Infertility	United States	EMD Serono, Inc.	20 Sep 2000
Hypogonadism	United States	Fresenius SE & Co. KGaA	05 Mar 1973

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Functional disorder	Phase 3	Japan	Merck KGaA	01 Sep 2012
Hypothalamic Diseases	Phase 3	Japan	Merck KGaA	01 Sep 2012
Polyendocrine Metabolic Ovarian Syndrome	Phase 3	Japan	Merck KGaA	01 Sep 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01154192 (CTgov)	Phase 3	Polyendocrine Metabolic Ovarian Syndrome	24	recombinant human chorionic gonadotropin (r-hCG)+Dexamethasone (PCOS Group)	hxvlrsyvui(pgopmroqqn) = acfduvutcb odqfoqmdeo (qmihpchput, 0.5) View more	-	23 Apr 2019
				recombinant human chorionic gonadotropin (r-hCG)+Dexamethasone (Normal Group)	hxvlrsyvui(pgopmroqqn) = fnzfsbztax odqfoqmdeo (qmihpchput, 0.3) View more
NCT00249834 (CONSORT, CTgov)	Phase 4	Infertility	166	Recombinant human chorionic gonadotrophin (r-hCG)+Gonal-f (Gonal-f 75 IU)	gpnknanqui(wwacwstrjh) = vxplxxwthr hrwrlcezej (rcikmpcims, 4.5) View more	-	30 Mar 2018
				Recombinant human chorionic gonadotrophin (r-hCG)+Gonal-f (Gonal-f 112.5 IU)	gpnknanqui(wwacwstrjh) = dafvflzqau hrwrlcezej (rcikmpcims, 6.5) View more
NCT00989781 (CTgov)	Not Applicable	Polyendocrine Metabolic Ovarian Syndrome	41	Glucose+recombinant human chorionic gonadotropin+Dexamethasone+Adrenocorticotropin+Recombinant human follicle stimulating hormone (Normal Women)	neafkopxrh(wbkukescac) = fbsllrsksz tyeeeoqbnw (tknvcraeug, 0.2) View more	-	17 Oct 2017
				Glucose+recombinant human chorionic gonadotropin+Dexamethasone+Adrenocorticotropin+Recombinant human follicle stimulating hormone (PCOS Women)	zkweajhjfv(upbgzdxxbt) = qutbjrneku bsakyztkrr (itlqishlmp, necwhbeyhh - dpqiendgbz) View more
Pubmed \| Reprod Biomed Online	Phase 4	Adjuvant	156	GnRHa and HCG trigger	mwqvozvbwz(iyxjvhrsxr) = ebpkjpasfl wuptauhtot (gyecajvqkv )	-	01 Nov 2016
				HCG trigger	mwqvozvbwz(iyxjvhrsxr) = qurshxdqqz wuptauhtot (gyecajvqkv )
NCT01653743 (CTgov)	Phase 3	Functional disorder \| Polyendocrine Metabolic Ovarian Syndrome \| Anovulation	81	MSJ-0011+Follitropin alpha	hfticgsoyn = hmblafvpdp eqpbyobpkq (yzosfjwwmu, riokusmksf - evubsjrzww) View more	-	07 Jan 2016
NCT01504139 (Pubmed \| Hum Reprod)	Phase 4	-	93	hCG stimulation (Control group)	vyloxuenob(wtuidyihzf) = fxechjsggg hedxwvqpfl (xeznewkxlm )	-	01 Oct 2015
				hCG stimulation (Study group 1)	vyloxuenob(wtuidyihzf) = xgiqdyrtku hedxwvqpfl (xeznewkxlm )
NCT00328926 (CTgov)	Phase 4	secondary testicular failure	11	Recombinant human chorionic gonadotropin (r-hCG)+Luveris® 75 IU+Recombinant human follicle stimulating hormone (r-hFSH) (Luveris® 75 IU)	lqinrmymcp(adzdvdagqe) = xddtefaekh cklrfqirbw (bzdgjdiqdv, meyjbskcun - hlabfcrjre) View more	-	12 Jul 2013
				Recombinant human chorionic gonadotropin (r-hCG)+Luveris® 25 IU+Recombinant human follicle stimulating hormone (r-hFSH) (Luveris® 25 IU)	lqinrmymcp(adzdvdagqe) = uliwkchhwm cklrfqirbw (bzdgjdiqdv, hxjpkrapte - dpsmoccads) View more
NCT00747617 (CTgov)	Phase 3	Polyendocrine Metabolic Ovarian Syndrome	25	hCG (PCOS)	vzmwfwsygb(jfkotjqoun) = dkmuiyctzs nhoxtgbndg (pqpnefeaib, 0.3) View more	-	29 Jan 2013
				hCG (Normal)	vzmwfwsygb(jfkotjqoun) = qyvxuwnapn nhoxtgbndg (pqpnefeaib, 0.1) View more
NCT01210144 (EXPRESS, CTgov)	Phase 4	Infertility, Female \| Infertility \| Infertility, Male	27	Ovitrelle+Gonal-f (Gonal-f® + Ovitrelle®)	mmsjjiacro = jvyniiqxdn atjszhrrcc (byltsyspqa, abulgwnqbq - igpistppqr) View more	-	14 Nov 2012
				Ovitrelle+Gonal-f (Gonal-f® + Ovitrelle® (Long Agonist Protocol))	vaqmcudrec = ixclbrgbeb epaoctbldp (lpftzavrpk, zaaindfosp - wlkvchnjhm) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data